Cargando…
PARK2 Regulates eIF4B-Driven Lymphomagenesis
Patients with high-risk diffuse large B-cell lymphoma have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP); thus, treatment of this fatal disease remains an area of unmet medical need and requires identification of novel therapeutic a...
Autores principales: | Kapadia, Bandish B., Roychowdhury, Anirban, Kayastha, Forum, Nanaji, Nahid, Gartenhaus, Ronald B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339581/ https://www.ncbi.nlm.nih.gov/pubmed/35191952 http://dx.doi.org/10.1158/1541-7786.MCR-21-0729 |
Ejemplares similares
-
Novel eIF4A1 inhibitors with anti‐tumor activity in lymphoma
por: Kayastha, Forum, et al.
Publicado: (2022) -
Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL
por: Kapadia, Bandish, et al.
Publicado: (2018) -
ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis
por: Perez-Oquendo, Mabel, et al.
Publicado: (2023) -
Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers
por: Maxwell, Pamela J., et al.
Publicado: (2022) -
Ecdysoneless Overexpression Drives Mammary Tumorigenesis through Upregulation of C-MYC and Glucose Metabolism
por: Mohapatra, Bhopal C., et al.
Publicado: (2022)